Celyad Oncology SA (CYAD.BR)
EUR 0.5
(4.35%)
EUR 0.5
(4.35%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -8.45 Million EUR | 79.3% |
| 2022 | -40.85 Million EUR | -54.81% |
| 2021 | -26.39 Million EUR | -0.58% |
| 2020 | -26.23 Million EUR | 10.67% |
| 2019 | -29.37 Million EUR | 23.05% |
| 2018 | -38.17 Million EUR | 27.81% |
| 2017 | -52.87 Million EUR | -106.47% |
| 2016 | -25.6 Million EUR | 13.69% |
| 2015 | -29.67 Million EUR | -80.52% |
| 2014 | -16.43 Million EUR | -37.33% |
| 2013 | -11.96 Million EUR | -730.67% |
| 2012 | -1.44 Million EUR | 84.14% |
| 2011 | -9.08 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.08 Million EUR | 0.0% |
| 2023 FY | -10.59 Million EUR | 74.06% |
| 2023 Q4 | -4.71 Million EUR | 0.0% |
| 2023 Q2 | -5.82 Million EUR | 0.0% |
| 2022 FY | -40.85 Million EUR | -54.81% |
| 2022 Q4 | -12.48 Million EUR | 0.0% |
| 2022 Q2 | -6.52 Million EUR | 13.52% |
| 2022 Q1 | -7.54 Million EUR | -85.62% |
| 2021 Q2 | -6.1 Million EUR | 30.44% |
| 2021 Q4 | -4.06 Million EUR | 45.39% |
| 2021 FY | -26.39 Million EUR | -0.58% |
| 2021 Q1 | -8.77 Million EUR | -279.32% |
| 2021 Q3 | -7.44 Million EUR | -22.02% |
| 2020 FY | -26.23 Million EUR | 10.67% |
| 2020 Q3 | -5.32 Million EUR | 67.0% |
| 2020 Q4 | 4.89 Million EUR | 191.89% |
| 2020 Q2 | -16.13 Million EUR | 0.0% |
| 2019 Q2 | -17.22 Million EUR | -143.49% |
| 2019 FY | -29.37 Million EUR | 23.05% |
| 2019 Q4 | -17.19 Million EUR | 0.0% |
| 2019 Q1 | -7.07 Million EUR | 57.33% |
| 2018 Q2 | -15.8 Million EUR | -69.19% |
| 2018 Q1 | -9.34 Million EUR | 33.83% |
| 2018 FY | -38.17 Million EUR | 27.81% |
| 2018 Q4 | -16.57 Million EUR | 0.0% |
| 2017 Q2 | -12.67 Million EUR | 9.9% |
| 2017 FY | -52.87 Million EUR | -106.47% |
| 2017 Q4 | -14.11 Million EUR | 0.0% |
| 2017 Q1 | -14.07 Million EUR | -109.06% |
| 2016 Q4 | -6.73 Million EUR | 0.0% |
| 2016 FY | -25.6 Million EUR | 13.69% |
| 2016 Q2 | -17.24 Million EUR | -193.48% |
| 2016 Q1 | -5.87 Million EUR | 58.58% |
| 2015 Q4 | -14.18 Million EUR | -95.57% |
| 2015 FY | -29.67 Million EUR | -80.52% |
| 2015 Q3 | -7.25 Million EUR | 52.2% |
| 2015 Q2 | -15.17 Million EUR | -109.2% |
| 2015 Q1 | -7.25 Million EUR | 29.81% |
| 2014 Q1 | -4.1 Million EUR | 40.78% |
| 2014 FY | -16.43 Million EUR | -37.33% |
| 2014 Q4 | -10.33 Million EUR | -151.57% |
| 2014 Q3 | -4.1 Million EUR | 35.97% |
| 2014 Q2 | -6.41 Million EUR | -56.17% |
| 2013 Q3 | -2.98 Million EUR | 50.47% |
| 2013 Q4 | -6.93 Million EUR | -132.76% |
| 2013 FY | -11.96 Million EUR | -730.67% |
| 2013 Q1 | -2.98 Million EUR | 0.0% |
| 2013 Q2 | -6.01 Million EUR | -101.91% |
| 2012 Q2 | -538.13 Thousand EUR | 0.0% |
| 2012 FY | -1.44 Million EUR | 84.14% |
| 2012 Q1 | -538.13 Thousand EUR | 0.0% |
| 2012 Q3 | -538.13 Thousand EUR | 0.0% |
| 2012 Q4 | -2.98 Million EUR | -453.8% |
| 2011 Q4 | -538.13 Thousand EUR | 76.43% |
| 2011 Q1 | -2.28 Million EUR | 0.0% |
| 2011 Q2 | -2.28 Million EUR | 0.0% |
| 2011 Q3 | -2.28 Million EUR | 0.0% |
| 2011 FY | -9.08 Million EUR | 0.0% |
| 2010 Q4 | -2.28 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nicox S.A. | -17.5 Million EUR | 51.683% |
| European Medical Solutions | -135 Thousand EUR | -6164.444% |
| FERMENTALG | -11.8 Million EUR | 28.379% |
| argenx SE | -417.15 Million EUR | 97.973% |
| BioSenic S.A. | -7.04 Million EUR | -20.128% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 47.121% |
| Onward Medical N.V. | -35.46 Million EUR | 76.153% |
| Oxurion NV | -12.11 Million EUR | 30.165% |
| PHAXIAM Therapeutics S.A. | -23.66 Million EUR | 64.256% |
| Financière de Tubize SA | -2.14 Million EUR | -294.454% |
| UCB SA | 604 Million EUR | 101.4% |